Relationship between GWG and adverse neonatal outcomes in different preconception BMI groups. by Feifei Jiang (11795243)

Subjects:

Association between GWG and adverse neonatal outcomes in maternal age at delivery subpopulations. by Feifei Jiang (11795243)

Subjects:

Adverse event list. by Stefan Halbherr (21353882)

“…No statistically significant improvements were seen in the Montreal Cognitive Assessment (MoCA) (mean decrease −0.73; 95% CI; −2.1, 0.62; <i>p</i> = 0.255), Epworth Sleepiness Scale (mean increase 0.09; 95% CI; −2.6, 2.8; <i>p</i> > 0.999), Beck Depression Inventory (BDI) (mean decrease −1.27; 95% CI; −3.8, 1.3; <i>p</i> = 0.257), and the Starkstein Apathy Scale (mean increase 0.36; 95% CI; −1.6, 2.4; <i>p</i> = 0.822). …”

Data Sheet 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.docx by Yi Li (1144)

Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events. by Jennifer M. Kwan (3350321)

Subjects:

Apoptotic gene expression without significant changes induced by propofol. by Yali Ge (417371)

Summary of duration of use, total dose received and adverse events. by Andrea R. Thurman (5286005)

Subjects:

Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE. by Jennifer M. Kwan (3350321)

Subjects:

Adverse pregnancy outcomes recorded among study participants. by Seth Amponsah-Tabi (13949142)

Subjects:

Quality of Antenatal care and adverse maternal and fetal outcomes. by Seth Amponsah-Tabi (13949142)

Subjects:

The incidence rate of adverse events. by Lipeng Shi (11307700)

“…Regarding safety, no difference was observed for adverse events (RR = 0.59, 95% <i>CI</i>, 0.22 to 1.54, <i>P</i> = 0.28).…”

Forest Plot of the incidence of adverse events in the MSCs therapy group and control group. by Luz Estella Mesa (8339283)

Subjects:

Key safety measures including adverse events. by Anuja Dokras (8679261)

The cGAS-STING axis is essential for <i>Schistosoma japonicum</i> infection-induced type I IFN response. by Le Liang (2144725)

Adverse events ^a. by Bruno Martins Tomazini (6509528)

“…There was no difference on bleeding episodes or serious adverse events at 28 days.</p><p>Conclusions</p><p>Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.…”

Transcription Factor (TF) activity and expression before adverse histopathology. by Anika Liu (8411805)

Subjects:

Incidence of surgical adverse events by fracture pattern, organized by case volume of the treating physician. by Taylor D. Ottesen (11185253)

Subjects:

Incidence of surgical adverse events by fracture pattern, organized by fellowship type of the treating physician. by Taylor D. Ottesen (11185253)

Subjects:

Forest Plot of the incidence of serious adverse events in MSCs therapy group and control group. by Luz Estella Mesa (8339283)

Subjects:

L’Abbé plot for the incidence of adverse events in the MSCs therapy group and control group. by Luz Estella Mesa (8339283)

Subjects: